Efficacy and mechanism of curcumin in prevention and treatment of diabetes, liver cirrhosis from nonalcoholic fatty liver disease (NAFLD), and osteoporosis in the patients with type 2 diabetes

Efficacy and mechanism of curcumin in prevention and treatment of diabetes, liver cirrhosis from nonalcoholic fatty liver disease (NAFLD), depression, and osteoporosis in the patients with type 2 diabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20140303003

Enrollment

296

Registered

2014-03-03

Start date

2014-05-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

curcuminoids extract type 2 diabetes insulin resistance obesity fatty liver osteoporosis curcuminoids extract type 2 diabetes insulin resistance obesity fatty liver osteoporosis

Interventions

Starch component,Curcuminoids component

Placebo Comparator Drug,Active Comparator Drug

Control,Active (Curcumin)

Eligibility

Sex/Gender

All

Age

25 Years to 65 Years

Inclusion criteria

Inclusion criteria: - type 2 diabetes patients

Exclusion criteria

Exclusion criteria: - type 1 diabetes - renal failure with serum creatinine > 2.0 md/dL - secondary cause of chronic hepatitis - Liver failure with AST and ALT over than 2.5 times of upper limit - heavy alcoholic drinking - receiving anti-hyperglycemic drugs ( TZD, DDP-IV inhibitor, insulin, GLP-1 agonist) and antihyperlipid drugs (fenofibrate, gemfibrozile and ezetrol) - receiving other herbal - secondary cause of hyperglycemia - history of inflammatory and infection diseases - pregnancy women - history of gall stone or cholecystectomy

Design outcomes

Primary

Measure	Time frame
Evaluate in the HOMA-Beta, pulse wave velocity, TNF-alpha, PHQ-9 scores 1 year t-test, Mann-Whitney U Test	—

Secondary

Measure	Time frame
fasting blood glucose, HbA1c, HOMA-IR, pro-inflammatory cytokines, cardiometabolic risks, anti-oxidant activities, oxidative stress, liver steatosis, liver stiffness, serotonin level, 1 year t-test, Mann-Whitney U Test	—

Countries

Thailand

Contacts

Public ContactSomlak Chuengsamarn

University

somlukc@swu.ac.th037395085

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026